Lung Cancer | Specialty

FDA Activity for Nivolumab and T-VEC in Melanoma, New Lung Cancer Results, and More

May 9th 2015

Dr. Michalski on Minimizing Long-Term Consequences of Radiation

May 5th 2015

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.

Taking Lung Cancer Care into the Precision Medicine Era

May 5th 2015

The recent approval of nivolumab in the non–small cell lung cancer setting marks a unique shift in the treatment landscape of this malignancy, one that harnesses the patient's own immune system to target the tumors. However, there are challenges in using these agents.

Ramucirumab Approval Expanded, Breakthrough Designation for Crizotinib, and More

May 2nd 2015

2015 AACR Annual Meeting Highlights

April 24th 2015

Dr. Camidge on MET as a Target in Lung Cancer

April 23rd 2015

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET and if it is still a relevant target in lung cancer.

Dr. Shaw on Overcoming Resistance in Lung Cancer

April 23rd 2015

Alice Tsang Shaw, MD, PhD, thoracic oncologist, Massachusetts General Hospital Cancer Center, discusses overcoming resistance to targeted therapy in lung cancer.

Dr. Herbst on Nivolumab for NSCLC

April 22nd 2015

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.

Dr. Welsh on New Understanding of Regulating PD-L1 Expression

April 21st 2015

James Welsh, MD, associate professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses a study that examined the regulation of PD-L1 and how it may open up more treatment options for patients with non-small cell lung cancer.

Crizotinib Granted Breakthrough Designation for ROS1-positive NSCLC

April 21st 2015

The FDA has granted a breakthrough therapy designation to crizotinib as a potential treatment for patients with ROS1-positive non–small cell lung cancer.

Dr. Evan Alley on KEYNOTE-028 Trial Results in Mesothelioma

April 20th 2015

Evan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.

Pembrolizumab Nears 50% Response in High PD-L1-Expressing NSCLC

April 19th 2015

Pembrolizumab had an overall response rate (ORR) of 45.2% among a cohort of patients with PD-L1-positive non–small cell lung cancer (NSCLC) and an ORR of nearly 20% in the full population in the phase I KEYNOTE-001 trial.

Dr. Heymach on New KRAS Subsets in Lung Cancer

April 19th 2015

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.

AZD9291 Shows Promising Response in T790M-Mutated NSCLC

April 17th 2015

Treatment with AZD9291 at 80 mg per day elicited a response in 66% of patients with EGFR T790M-positive non–small cell lung cancer.

Nivolumab Improves Survival in Phase III Nonsquamous NSCLC Study

April 17th 2015

Nivolumab (Opdivo) improved survival versus docetaxel in patients with pretreated nonsquamous non–small cell lung cancer in the phase III CheckMate-057 trial.

Brigatinib Achieves Brain Metastases Control for Over 80% of ALK-Positive NSCLC Patients

April 17th 2015

Brigatinib, an investigational ALK tyrosine kinase inhibitor, demonstrated significant intracranial antitumor activity in patients with ALK-positive non–small cell lung cancer and brain metastases.

Dr. Tracey Evans on Treatment of Poor PS and Elderly Patients With Lung Cancer

April 3rd 2015

Tracey L. Evans, MD, associate professor of clinical medicine, University of Pennsylvania Health System, discusses treatment of poor performance status (PS) and elderly patients with lung cancer.

Lung Cancer Pioneer Thomas Lynch Discusses the State of the Art

April 2nd 2015

Thomas Lynch, who is director of the Yale Cancer Center and physician-in-chief at the Smilow Cancer Hospital at Yale-New Haven, recently sat down with OncLive and discussed key strategies and trends in the management of lung cancer.

Maintenance Strategies After Initial Chemotherapy for Non-Small Cell Lung Cancer

April 1st 2015

James P. Stevenson, MD, discusses optimization of drug and patient selection for maintenance therapies in NSCLC, and how it will continue to be a research focus in today's environment of value-based care.

Study Suggests Lung Cancer Screening Criteria May Not Capture All Smokers Who Need It

March 31st 2015

Eligibility criteria set by the Centers for Medicare & Medicaid Services for coverage of low-dose computed tomography for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening.